The effects of SARS-CoV-2 variants on disease phenotype and severity of multisystem inflammatory syndrome in children (MIS-C) are unknown. We compared the clinical phenotype of MIS-C in 129 South African children across four distinct (Ancestral type, Beta, Delta, and Omicron) variant-driven waves and found that MIS-C remains a severe disease with a stable clinical presentation, regardless of variant.
14 October 2026 in The Pediatric Infectious Disease Journal
Background: The COVID-19 pandemic disrupted respiratory virus epidemiology. We describe the postpandemic prevalence, seasonality and clinical presentation of viral respiratory tract infections (RTIs) among hospitalized South African children. Methods: Children 0–<13 years of age with acute RTIs were prospectively enrolled between October 2024 and October 2025. Nasopharyngeal aspirates were collected on admission and tested for 7 common respiratory viruses using a multiplex real-time polymerase chain reaction. Clinical, demographic and outcome data were recorded. Disease severity was classified as mild, moderate or severe based on the need for hospitalization, respiratory support, intensive care or major complications. Cluster analysis identified distinct clinical phenotypes. Results: We enrolled 315 children, median age 9.3 months [interquartile range 3.6–24.7, 132/315 (41.9%) female, 7/315 (2.2%) living with HIV and 53/315 (16.8%) HIV-exposed but uninfected. Disease severity was mild in 55 (17.5%), moderate in 184 (58.4%) and severe in 76 (24.1%) children. Respiratory viruses were detected in 276/315 (87.6%); most commonly human rhinovirus (167/276; 60.5%), respiratory syncytial virus (94/276; 34%) and adenovirus (59/315; 18.7%). Respiratory syncytial virus showed strong winter seasonality ( P < 0.001), human rhinovirus circulated year-round ( P < 0.001) and seasonal Severe acute respiratory syndrome coronavirus-2 activity was low at 10%. HIV exposure (adjusted odds ratio: 3.08)] and viral co-detection (43.5%; P = 0.015) were independently associated with disease severity. Cluster analysis revealed 3 distinct clinical phenotypes of RTIs, with unique symptom profiles, trajectories and virological patterns. Conclusion: Respiratory viruses remained common in young South African children hospitalized with RTIs, with most returning to pre-COVID seasonal patterns and limited Severe acute respiratory syndrome coronavirus-2 activity. Distinct clinical phenotypes identify vulnerable subgroups and underscore the need for improved tools to distinguish severe disease from self-limiting illness.
Oxylipins derived from dietary polyunsaturated fatty acids (PUFAs) are key determinants of intestinal health, homeostasis and inflammatory disorders, such as colitis-associated colorectal cancer (CAC). Previous research has independently linked a high dietary omega (ω)-6:ω-3 PUFA ratio, or intestinal helminth infection, to an increased risk of CAC. However, whether these two factors interact to exacerbate disease risk and whether oxylipins contribute to this is unknown. In this study, we report that infection with the helminth Heligmosomoides polygyrus bakeri (Hpb) exacerbates tumour formation when combined with a high ω-6:ω-3 PUFA ratio diet. Dietary increases in tumour burden correlated with heightened levels of arachidonic acid (AA) and AA-derived lipoxygenase (LOX) oxylipins in the colon, including the 12/15-LOX product 12-hydroxyeicosatetraenoic acid, prior to disease onset. Although helminth infection further increased the production of 12/15-LOX oxylipins and increased expression of Alox15, responsible for producing these metabolites, inhibition of cyclooxygenase-dependent prostaglandin production with aspirin prevented helminth-exacerbation of disease. Helminth-infected mice exhibited increased phosphorylation of β-catenin in the colon, which was inhibited by EP2 and 4 antagonists. Moreover, administration of an EP agonist increased tumour burden in naive mice fed a high ω-6:ω-3 PUFA ratio diet, to the levels seen in helminth-exacerbation of disease. These data suggest that dietary changes in fatty acid composition coordinate with helminth-induced activation of EP signalling to exacerbate tumour development.
Kaposi’s Sarcoma-associated herpesvirus (KSHV) and Epstein–Barr virus (EBV) are oncogenic gammaherpesviruses with high prevalence in sub-Saharan Africa. Both viruses are typically acquired during childhood, establishing lifelong latency. While viral reactivation into the lytic cycle has been mainly studied in adult HIV-infected populations—and more recently in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection—the dynamics of KSHV and EBV infection in children remain poorly understood. Here, we characterize pediatric patients (n = 175; median age 4.6 years; IQR 2.0–8.3) presenting with inflammatory conditions during the COVID-19 pandemic in South Africa (from July 2020 to February 2024). Including a healthy, non-inflammatory control group, we found widespread exposure to SARS-CoV-2 (70.9% seropositivity), with 72.6% of the children being seropositive for EBV and 19.4% for KSHV. There were no significant differences in seroprevalence between children with inflammatory conditions and healthy controls for any of these viruses, although SARS-CoV-2 antibody titers were significantly higher in the inflammatory group, while EBV immune responses were lower in children presenting with inflammation. Among the KSHV-seropositive children, no active viremia was detected (as determined by the absence of viral DNA in the peripheral blood). In contrast, 34.4% of EBV-seropositive children had detectable EBV viral load, with a modestly higher proportion in the inflammatory group. However, EBV viral load levels were comparable between children diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease (KD), and other inflammatory conditions. Logistic regression analyses revealed that increasing age was significantly associated with higher risk of SARS-CoV-2 and EBV seropositivity, but not KSHV. Notably, the risk of EBV DNA detection in the peripheral blood decreased with age. In summary, this study suggests effective immunological control of gammaherpesvirus infections in HIV-negative paediatric patients, even in the presence of inflammatory conditions that might otherwise trigger viral reactivation.
1 January 2026 in Southern African Journal of HIV Medicine
Background: Since 2019 dolutegravir-based antiretroviral therapy (ART) has been introduced for South African children and adolescents living with HIV (CALHIV), including those with persistent viral non-suppression. Current guidelines recommend the reuse of abacavir when switching CALHIV weighing < 30 kg with persistent viral non-suppression to dolutegravir-based ART. Objectives: We aimed to describe the viral suppression rates, clinical outcomes and risk factors for non-suppression in CALHIV switching to dolutegravir-based ART following persistent viral non-suppression. Method: We performed a retrospective cohort study at Tygerberg Hospital in Cape Town, South Africa. Results: We identified 39 children, 18 girls (46.2%). Median age at switch to a dolutegravir-based regimen was 7.2 years. Median duration on treatment pre-switch was 5.6 years. After switching to a dolutegravir-based regimen, 21 children (55.3%) achieved viral suppression. Abacavir was recycled with dolutegravir in 31 children (available viral load for 30/31) of whom 50.0% suppressed. Treatment interruptions were common, with 26 (66.7%) and 15 (38.5%) children experiencing at least one interruption in care before and after switching to a dolutegravir-based regimen, respectively. Conclusion: We provide evidence that recycling abacavir is safe in children with persistent viral non-suppression switching to dolutegravir. Supporting adherence and preventing therapy interruption is key to success.